

FORM 51 – 102F3

MATERIAL CHANGE REPORT

1. Name and Address of Company

bioMmune Technologies Inc.
1780 – 400 Burrard Street
Vancouver, BC V6C 3A6

2. Date of Material Change

May 3, 2015

3. News Release

A news release dated May 3, 2015 was disseminated through Marketwired and was filed via SEDAR on May 4, 2015.

4. Summary of the Material Change

BioMmune Technologies Inc. Announces Non-Brokered Private Placement.

5. Full Description of the Material Change

BioMmune Technologies Inc. (the “Company”) (TSX.V: IMU), announces a non-brokered private placement of up to 5,000,000 units (each a “Unit”) at a price of \$0.20 per Unit for gross proceeds of up to \$1,000,000. Each Unit will consist of one common share and one common share purchase warrant (each a “Warrant”). Each Warrant entitles the holder to purchase one additional common share of the Company at a price of \$0.30 per share for a period of eighteen months from the date of closing, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the Company may exercise once the Units are free of resale restrictions and if the Company’s shares are trading at or above a volume weighted average price of \$0.50 for 10 consecutive trading days, the Warrants will expire upon 30 days from the date the Company provides notice in writing to the Warrant holders via a news release.

A finder’s fee of up to 8% of the proceeds from the sale of units may be paid in cash in connection with the private placement.

The proceeds from the sale of units will be added to working capital in furtherance of the Company’s business. The securities to be issued under the placement will be subject to a four-month hold period and the private placement is subject to the acceptance of the TSX Venture Exchange.

6. Reliance on subsection 7.1(2) or (3) of National Instrument 51 – 102

N/A

7. Omitted Information

N/A

8. Executive Officer

Dr. Reinhard Gabathuler, President
Phone: (514) 963-6177

9. Date of Report

May 7, 2015